Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality.

ABSTRACT:

Background

 Mortality in coronavirus disease of 2019 (COVID-19) is associated with increases in prothrombotic parameters, particularly D-dimer levels. Anticoagulation has been proposed as therapy to decrease mortality, often adjusted for illness severity.

Objective

 We wanted to investigate whether anticoagulation improves survival in COVID-19 and if this improvement in survival is associated with disease severity.

Methods

 This is a cohort study simulating an intention-to-treat clinical trial, by analyzing the effect on mortality of anticoagulation therapy chosen in the first 48 hours of hospitalization. We analyzed 3,625 COVID-19+ inpatients, controlling for age, gender, glomerular filtration rate, oxygen saturation, ventilation requirement, intensive care unit admi

SUBMITTER: Billett HH 

PROVIDER: S-EPMC7869055 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature